Rybrevant 350 MG/7 ML vial 7ML
Ended Awarded
- Contract number
- SPE2DB25FWU17
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,445
Award facts
- Contract value 100% obligated
- $13,445.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rybrevant (selpercatinib) 350 mg/7 ml vials valued at $13,445.10. This order represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. Rybrevant is a targeted cancer therapy used for treating RET-altered non-small cell lung cancer, representing the specialized oncology medications that fall within the scope of this comprehensive global pharmaceutical support contract.
This delivery order is one of numerous pharmaceutical procurements fulfilled by AmerisourceBergen through its DLA Troop Support Medical prime contract vehicle, which supplies medications and medical commodities to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The contract employs firm fixed pricing for all deliveries and reflects AmerisourceBergen's established role as a critical pharmaceutical distributor for federal medical supply needs. The non-set-aside award demonstrates the company's competitive standing in federal procurement and its capability to fulfill specialized pharmaceutical requirements across multiple therapeutic domains for the Department of Defense healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FWU17?
SPE2DB25FWU17 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 8, 2025.
How much is contract SPE2DB25FWU17 worth?
The government has obligated $13,445 on SPE2DB25FWU17.
Is contract SPE2DB25FWU17 an order under another contract?
Yes. SPE2DB25FWU17 is a delivery order under SPE2DB22D3501, an indefinite delivery contract.
Was contract SPE2DB25FWU17 competed?
The extent of competition for SPE2DB25FWU17 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award